Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT04802356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04802356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 7, 2021
Completion date
June 30, 2026
Enrollment
50 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma